The treatment landscape for hormone receptor positive, HER2 negative advanced breast cancer may soon undergo a meaningful shift. In January 2026, Celcuity Inc. announced that the US Food and Drug Administration has accepted its New Drug Application for gedatolisib, an investigational therapy targeting the PI3K, AKT, and mTOR signaling pathway. The FDA also granted Priority Review and assigned a PDUFA target date of July 17, 2026.
This development is particularly significant for patients with HR positive, HER2 negative, PIK3CA wild type advanced breast cancer, a group that has historically had limited targeted treatment options. The acceptance of this NDA places gedatolisib one step closer to potential FDA approval and eventual clinical use.
This article explores what gedatolisib is, why the FDA acceptance matters, how it differs from existing therapies, and what this could mean for patients and clinicians navigating advanced breast cancer care.
Breast cancer is not a single disease. It consists of multiple subtypes defined by molecular and receptor characteristics. HR positive, HER2 negative breast cancer is the most common subtype, accounting for roughly two thirds of all breast cancer cases.
In early stages, this cancer type is often treated successfully with surgery, radiation, endocrine therapy, or a combination of approaches. However, once the disease becomes advanced or metastatic, treatment becomes more complex. Resistance to endocrine therapy frequently develops over time, driving disease progression.
One of the most important molecular pathways involved in this resistance is the PI3K, AKT, and mTOR pathway, often referred to as the PAM pathway. This signaling cascade plays a central role in cell growth, survival, and metabolism. Dysregulation of this pathway is common in advanced breast cancer and is associated with poorer outcomes.
Several approved targeted therapies address PAM pathway activation in patients whose tumors carry PIK3CA mutations. Drugs such as alpelisib have improved outcomes in this specific population. However, a substantial proportion of patients with HR positive, HER2 negative advanced breast cancer do not have PIK3CA mutations.
For these PIK3CA wild type patients, treatment options targeting the PAM pathway have been limited. Single node inhibitors often fail to provide durable benefit because blocking one component of the pathway can lead to compensatory activation of others. This adaptive resistance has been a major obstacle in drug development.
Gedatolisib was designed specifically to overcome this limitation.
Gedatolisib is an investigational, multi target inhibitor of the PI3K, AKT, and mTOR signaling pathway. Unlike currently approved therapies that focus on a single enzyme or node, gedatolisib potently inhibits all four Class I PI3K isoforms as well as mTORC1 and mTORC2.
This comprehensive blockade is intended to suppress pathway signaling more effectively and prevent the feedback activation that commonly limits the efficacy of single target drugs.
Preclinical studies and early clinical data suggest that gedatolisib demonstrates comparable potency and cytotoxic activity in both PIK3CA mutant and wild type breast cancer cells. This characteristic makes it particularly promising for patients who lack actionable mutations but still exhibit pathway dependence.
The FDA acceptance of a New Drug Application means that the agency has completed an initial review and determined that the submission is sufficiently complete to proceed with a full regulatory evaluation. This is a critical milestone in the drug development process.
In addition to acceptance, the FDA granted Priority Review to gedatolisib. Priority Review is reserved for therapies that may offer significant improvements in the treatment of serious conditions. Under this designation, the FDA aims to complete its review within six months instead of the standard ten months.
The assigned PDUFA goal date of July 17, 2026 sets a clear regulatory timeline and signals the FDA’s recognition of the unmet medical need in this patient population.
Gedatolisib is also being reviewed under the FDA’s Real Time Oncology Review program. This initiative allows the FDA to assess clinical data as it becomes available, potentially accelerating the overall approval process.
The NDA submission is based on data from the Phase 3 VIKTORIA 1 clinical trial, specifically from the PIK3CA wild type cohort. This randomized study evaluated gedatolisib in combination with fulvestrant, with or without palbociclib, in patients with HR positive, HER2 negative advanced breast cancer.
According to Celcuity, the dataset demonstrated robust efficacy and safety outcomes that support the drug’s potential to change clinical practice. Earlier phase studies have also shown encouraging results, including meaningful tumor responses and manageable toxicity profiles.
Notably, gedatolisib has previously received Breakthrough Therapy and Fast Track designations from the FDA. These designations are based on preliminary clinical evidence suggesting substantial improvement over existing therapies.
Most currently approved PAM pathway inhibitors focus on a single molecular target. While effective in certain settings, these drugs often trigger adaptive resistance mechanisms that limit long term benefit.
Gedatolisib’s multi target approach is its key differentiator. By simultaneously inhibiting PI3K isoforms and both mTOR complexes, the drug aims to shut down pathway signaling more completely. This strategy may reduce the likelihood of compensatory activation and improve durability of response.
Another important distinction is its activity in PIK3CA wild type tumors. This expands the potential patient population and addresses a longstanding gap in advanced breast cancer treatment.
If approved, gedatolisib could become a new standard option for patients with HR positive, HER2 negative advanced breast cancer, particularly those without PIK3CA mutations. It may also provide an additional line of therapy for patients who have progressed on endocrine therapy and CDK4/6 inhibitors.
For clinicians, the availability of a comprehensive PAM pathway inhibitor could simplify treatment decision making and reduce the need for strict molecular selection. It may also encourage further exploration of combination strategies aimed at delaying resistance and improving survival.
From a patient perspective, the potential approval of gedatolisib represents hope for more effective disease control and improved quality of life in a setting where treatment choices are often limited.
Between now and the July 2026 PDUFA date, the FDA will conduct a detailed evaluation of the clinical, safety, and manufacturing data submitted by Celcuity. This process may include requests for additional information or analyses.
If approved, Celcuity plans to move forward with commercialization and continued clinical development. Ongoing studies, including the Phase 3 VIKTORIA 2 trial and trials in other tumor types, suggest that the role of gedatolisib may expand beyond advanced breast cancer in the future.
The FDA’s acceptance of Celcuity’s New Drug Application for gedatolisib marks a pivotal moment in the evolution of targeted therapies for advanced breast cancer. With its novel multi target mechanism and demonstrated activity in PIK3CA wild type disease, gedatolisib has the potential to address a critical unmet need.
While approval is not guaranteed, the Priority Review designation and strong clinical foundation position gedatolisib as one of the most closely watched oncology drugs of 2026. Patients, clinicians, and researchers alike will be following the FDA review process with great interest.
Celcuity Inc. Press Release, January 20, 2026
Venkatesan AM et al. Journal of Medicinal Chemistry, 2010
Mallon R et al. Clinical Cancer Research, 2011
Rossetti S et al. NPJ Breast Cancer, 2024
Layman R et al. Lancet Oncology, 2024
This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare professional with any questions regarding medical conditions or treatment decisions. Drug approval status and clinical recommendations may change over time based on new evidence and regulatory decisions.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.